OncoMatch/Clinical Trials/NCT04858009
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Is NCT04858009 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cisplatin and Hyperthermic Intraperitoneal Chemotherapy for metastatic pancreatic carcinoma.
Treatment: Cisplatin · Hyperthermic Intraperitoneal Chemotherapy · Nab-paclitaxel — This phase II trial studies the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with pancreatic cancer that has spread to the internal abdominal area (peritoneal metastasis). Chemotherapy drugs, such as nab-paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. HIPEC involves "heated" chemotherapy that is placed directly in the abdomen through laparoscopic instruments, instead of through an intravenous injection. This study may help doctors determine how safe and effective HIPEC work in treating patient with pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS any tested
KRASD assay positive peritoneal washings/cytology
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic chemotherapy — preoperative
Completion of preoperative systemic chemotherapy with biochemical, metabolic, and/or radiographic response
Cannot have received: protocol systemic chemotherapy
Exception: hypersensitivity that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
Lab requirements
Blood counts
leukocytes >= 3,000/ul; absolute neutrophil count >= 1,500/ul; platelets >= 60,000/ul
Kidney function
serum creatinine =< 1.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04858009 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior protocol systemic chemotherapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages